|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Ward EM, Johnson CJ, Cronin KA,
Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al:
Annual Report to the Nation on the Status of Cancer, 1975–2014,
Featuring Survival. J Natl Cancer Inst. 109:2017. View Article : Google Scholar
|
|
3
|
Wang G, Chan CH, Gao Y and Lin HK: Novel
roles of Skp2 E3 ligase in cellular senescence, cancer progression,
and metastasis. Chin J Cancer. 31:169–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Frescas D and Pagano M: Deregulated
proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the
scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan CH, Morrow JK, Zhang S and Lin HK:
Skp2: A dream target in the coming age of cancer therapy. Cell
Cycle. 13:679–680. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu M, Ma J, Xue W, Cheng C, Wang Y, Zhao
Y, Ke Q, Liu H, Liu Y, Li P, et al: The expression and prognosis of
FOXO3a and Skp2 in human hepatocellular carcinoma. Pathol Oncol
Res. 15:679–687. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei X, Li X, Yan W, Zhang X, Sun Y and
Zhang F: SKP2 promotes hepatocellular carcinoma progression through
nuclear AMPK-SKP2-CARM1 signaling transcriptionally regulating
nutrient-deprived autophagy induction. Cell Physiol Biochem.
47:2484–2497. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen A, Wang H, Zhang Y, Wang X, Yu L, Xu
W, Xu W and Lin Y: Paeoniflorin exerts neuroprotective effects
against glutamateinduced PC12 cellular cytotoxicity by inhibiting
apoptosis. Int J Mol Med. 40:825–833. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu P, Zhu L, Liu Y, Zhang L, Liu J and
Shen H: Protective effects of paeoniflorin on TNBS-induced
ulcerative colitis through inhibiting NF-kappaB pathway and
apoptosis in mice. Int Immunopharmacol. 50:152–160. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kapoor S: The emerging antineoplastic
effects of paeoniflorin. Anticancer Drugs. 24:4292013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu Z, Qin F, Gao S, Zhen Y, Huang D and
Dong L: Paeoniflorin exerts protective effect on radiation-induced
hepatic fibrosis in rats via TGF-β1/Smads signaling pathway. Am J
Transl Res. 10:1012–1021. 2018.PubMed/NCBI
|
|
13
|
Li JZ, Tang XN, Li TT, Liu LJ, Yu SY, Zhou
GY, Shao QR, Sun HP, Wu C and Yang Y: Paeoniflorin inhibits
doxorubicin-induced cardiomyocyte apoptosis by downregulating
microRNA-1 expression. Exp Ther Med. 11:2407–2412. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu JT, He W, Song SS and Wei W:
Paeoniflorin inhibited the tumor invasion and metastasis in human
hepatocellular carcinoma cells. Bratisl Lek Listy. 115:427–433.
2014.PubMed/NCBI
|
|
15
|
Wang H, Zhou H, Wang CX, Li YS, Xie HY,
Luo JD and Zhou Y: Paeoniflorin inhibits growth of human colorectal
carcinoma HT 29 cells in vitro and in vivo. Food Chem Toxicol.
50:1560–1567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang Z, Chen W, Yan X, Bi L, Guo S and
Zhan Z: Paeoniflorin protects cells from GalN/TNF-α-induced
apoptosis via ER stress and mitochondria-dependent pathways in
human L02 hepatocytes. Acta Biochim Biophys Sin (Shanghai).
46:357–367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Ye X, Cai X, Su J, Ma R, Yin X,
Zhou X, Li H and Wang Z: Curcumin suppresses cell growth and
invasion and induces apoptosis by down-regulation of Skp2 pathway
in glioma cells. Oncotarget. 6:18027–18037. 2015.PubMed/NCBI
|
|
18
|
Yin X, Zhang Y, Su J, Hou Y, Wang L, Ye X,
Zhao Z, Zhou X, Li Y and Wang Z: Rottlerin exerts its anti-tumor
activity through inhibition of Skp2 in breast cancer cells.
Oncotarget. 7:66512–66524. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang Y, Zhao M, Xu H, Wang K, Fu Z, Jiang
Y and Yao Z: RASAL2 down-regulation in ovarian cancer promotes
epithelial-mesenchymal transition and metastasis. Oncotarget.
5:6734–6745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X,
Zhou X, Zhou L and Wang Z: Rottlerin inhibits cell growth and
invasion via down-regulation of Cdc20 in glioma cells. Oncotarget.
7:69770–69782. 2016.PubMed/NCBI
|
|
22
|
Shin E, Kim SH, Jeong HY, Jang JJ and Lee
K: Nuclear expression of S-phase kinase-associated protein 2
predicts poor prognosis of hepatocellular carcinoma. Apmis.
120:349–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi M, Liu D, Zhang S, Hu P and Sang T:
Inhibition of S-phase kinase-associated protein 2-mediated p27
degradation suppresses tumorigenesis and the progression of
hepatocellular carcinoma. Mol Med Rep. 11:3934–3940. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Delogu S, Wang C, Cigliano A, Utpatel K,
Sini M, Longerich T, Waldburger N, Breuhahn K, Jiang L, Ribback S,
et al: SKP2 cooperates with N-Ras or AKT to induce liver tumor
development in mice. Oncotarget. 6:2222–2234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang S, Chen Q, Liu Q, Li Y, Sun X, Hong
L, Ji S, Liu C, Geng J, Zhang W, et al: Hippo signaling suppresses
cell ploidy and tumorigenesis through Skp2. Cancer Cell.
31:669–684,e7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calvisi DF, Ladu S, Pinna F, Frau M,
Tomasi ML, Sini M, Simile MM, Bonelli P, Muroni MR, Seddaiu MA, et
al: SKP2 and CKS1 promote degradation of cell cycle regulators and
are associated with hepatocellular carcinoma prognosis.
Gastroenterology. 137:1816–1826,e1-10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalra N and Kumar V: The X protein of
hepatitis B virus binds to the F box protein Skp2 and inhibits the
ubiquitination and proteasomal degradation of c-Myc. FEBS Lett.
580:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Y, Tai AW, Tong S and Lok AS: HBV
core promoter mutations promote cellular proliferation through
E2F1-mediated upregulation of S-phase kinase-associated protein 2
transcription. J Hepatol. 58:1068–1073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang Y, Tong S, Tai AW, Hussain M and Lok
AS: Hepatitis B virus core promoter mutations contribute to
hepatocarcinogenesis by deregulating SKP2 and its target, p21.
Gastroenterology. 141:1412–1421, e1-e5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang H, Ozaki I, Mizuta T, Yoshimura T,
Matsuhashi S, Hisatomi A, Tadano J, Sakai T and Yamamoto K:
Mechanism of beta 1-integrin-mediated hepatoma cell growth involves
p27 and S-phase kinase-associated protein 2. Hepatology.
38:305–313. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu S, Sun W, Wei W, Wang D, Jin J, Wu J,
Chen J, Wu H and Wang Q: Involvement of the prostaglandin E
receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis.
Anticancer Drugs. 24:140–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ouyang J, Xu H, Li M, Dai X, Fu F, Zhang X
and Lan Q: Paeoniflorin exerts antitumor effects by inactivating S
phase kinase-associated protein 2 in glioma cells. Oncol Rep.
39:1052–1062. 2018.PubMed/NCBI
|
|
33
|
Zhong WB, Tsai YC, Chin LH, Tseng JH, Tang
LW, Horng S, Fan YC and Hsu SP: A synergistic anti-cancer effect of
troglitazone and lovastatin in a human anaplastic thyroid cancer
cell line and in a mouse xenograft model. Int J Mol Sci. 19(pii):
E18342018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motomura W, Takahashi N, Nagamine M,
Sawamukai M, Tanno S, Kohgo Y and Okumura T: Growth arrest by
troglitazone is mediated by p27Kip1 accumulation, which results
from dual inhibition of proteasome activity and Skp2 expression in
human hepatocellular carcinoma cells. Int J Cancer. 108:41–46.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo W, Chen Y, Liu M, Du K, Zheng G, Cai
T, Zhang W, Zhao F, Yao T, Yang R and Chen J: EB1089 induces
Skp2-dependent p27 accumulation, leading to cell growth inhibition
and cell cycle G1 phase arrest in human hepatoma cells. Cancer
Invest. 27:29–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liao YJ, Bai HY, Li ZH, Zou J, Chen JW,
Zheng F, Zhang JX, Mai SJ, Zeng MS, Sun HD, et al: Longikaurin A, a
natural ent-kaurane, induces G2/M phase arrest via downregulation
of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in
hepatocellular carcinoma cells. Cell Death Dis. 5:e11372014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang ST, Ho HJ, Lin JT, Shieh JJ and Wu
CY: Simvastatin-induced cell cycle arrest through inhibition of
STAT3/SKP2 axis and activation of AMPK to promote p27 and p21
accumulation in hepatocellular carcinoma cells. Cell Death Dis.
8:e26262017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng S, Wang Y, Zhang R, Yang G, Liang Z,
Wang Z and Zhang G: Curcumin exerts its antitumor activity through
regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.
Onco Targets Ther. 10:2377–2388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su J, Zhou X, Wang L, Yin X and Wang Z:
Curcumin inhibits cell growth and invasion and induces apoptosis
through down-regulation of Skp2 in pancreatic cancer cells. Am J
Cancer Res. 6:1949–1962. 2016.PubMed/NCBI
|
|
40
|
Su J, Wang L, Yin X, Zhao Z, Hou Y, Ye X,
Zhou X and Wang Z: Rottlerin exhibits anti-cancer effect through
inactivation of S phase kinase-associated protein 2 in pancreatic
cancer cells. Am J Cancer Res. 6:2178–2191. 2016.PubMed/NCBI
|
|
41
|
Dituri F, Mazzocca A, Fernando J, Peidrò
FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabbà C and
Giannelli G: Differential inhibition of the TGF-β signaling pathway
in HCC cells using the small molecule inhibitor LY2157299 and the
D10 monoclonal antibody against TGF-β receptor Type II. PLoS One.
8:e671092013. View Article : Google Scholar : PubMed/NCBI
|
